Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena, Rome, Italy.
PLoS Pathog. 2012;8(6):e1002774. doi: 10.1371/journal.ppat.1002774. Epub 2012 Jun 21.
Stably suppressed viremia during ART is essential for establishing reliable simian models for HIV/AIDS. We tested the efficacy of a multidrug ART (highly intensified ART) in a wide range of viremic conditions (10³-10⁷) viral RNA copies/mL) in SIVmac251-infected rhesus macaques, and its impact on the viral reservoir. Eleven macaques in the pre-AIDS stage of the disease were treated with a multidrug combination (highly intensified ART) consisting of two nucleosidic/nucleotidic reverse transcriptase inhibitors (emtricitabine and tenofovir), an integrase inhibitor (raltegravir), a protease inhibitor (ritonavir-boosted darunavir) and the CCR5 blocker maraviroc. All animals stably displayed viral loads below the limit of detection of the assay (i.e. <40 RNA copies/mL) after starting highly intensified ART. By increasing the sensitivity of the assay to 3 RNA copies/mL, viral load was still below the limit of detection in all subjects tested. Importantly, viral DNA resulted below the assay detection limit (<2 copies of DNA/5*10⁵ cells) in PBMCs and rectal biopsies of all animals at the end of the follow-up, and in lymph node biopsies from the majority of the study subjects. Moreover, highly intensified ART decreased central/transitional memory, effector memory and activated (HLA-DR⁺) effector memory CD4⁺ T-cells in vivo, in line with the role of these subsets as the main cell subpopulations harbouring the virus. Finally, treatment with highly intensified ART at viral load rebound following suspension of a previous anti-reservoir therapy eventually improved the spontaneous containment of viral load following suspension of the second therapeutic cycle, thus leading to a persistent suppression of viremia in the absence of ART. In conclusion, we show, for the first time, complete suppression of viral load by highly intensified ART and a likely associated restriction of the viral reservoir in the macaque AIDS model, making it a useful platform for testing potential cures for AIDS.
ART 期间稳定抑制病毒血症对于建立可靠的 HIV/AIDS 猴模型至关重要。我们在 SIVmac251 感染的恒河猴中测试了一种多药物 ART(高度强化 ART)在广泛的病毒血症条件下(10³-10⁷)病毒 RNA 拷贝/mL),并研究了其对病毒储存库的影响。11 只处于疾病 AIDS 前期的猕猴接受了一种多药物组合(高度强化 ART)治疗,该组合包括两种核苷/核苷酸逆转录酶抑制剂(恩曲他滨和替诺福韦)、一种整合酶抑制剂(拉替拉韦)、一种蛋白酶抑制剂(利托那韦增强的达芦那韦)和 CCR5 阻滞剂马拉维若。所有动物在开始高度强化 ART 后,病毒载量均稳定低于检测限(即 <40 RNA 拷贝/mL)。通过将检测灵敏度提高到 3 RNA 拷贝/mL,所有受试动物的病毒载量仍低于检测限。重要的是,在随访结束时,所有动物的 PBMC 和直肠活检中的病毒 DNA 均低于检测限(<2 拷贝 DNA/5*10⁵ 个细胞),大多数研究对象的淋巴结活检也如此。此外,高度强化 ART 降低了体内中央/过渡记忆、效应记忆和激活(HLA-DR⁺)效应记忆 CD4⁺ T 细胞,这与这些亚群作为携带病毒的主要细胞亚群的作用一致。最后,在先前抗储存库治疗暂停后病毒载量反弹时,使用高度强化 ART 治疗最终改善了第二个治疗周期暂停后病毒载量的自发控制,从而导致在没有 ART 的情况下持续抑制病毒血症。总之,我们首次证明了高度强化 ART 可完全抑制病毒载量,并可能限制猴 AIDS 模型中的病毒储存库,使其成为测试 AIDS 潜在治愈方法的有用平台。